Quest Diagnostics Incorporated (DGX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Quest Diagnostics Incorporated (DGX) has a cash flow conversion efficiency ratio of 0.036x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($278.00 Million) by net assets ($7.67 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Quest Diagnostics Incorporated liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Quest Diagnostics Incorporated - Cash Flow Conversion Efficiency Trend (1996–2025)
This chart illustrates how Quest Diagnostics Incorporated's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Quest Diagnostics Incorporated Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Quest Diagnostics Incorporated ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
CIMB Group Holdings Bhd
KLSE:1023
|
0.009x |
|
Guangdong Songfa Ceramics Co
SHG:603268
|
-0.060x |
|
Expand Energy Corporation
NASDAQ:EXE
|
0.123x |
|
Veralto Corporation
NYSE:VLTO
|
0.095x |
|
Cognizant Technology Solutions Corp Class A
NASDAQ:CTSH
|
0.018x |
|
Hapag Lloyd AG
XETRA:HLAG
|
0.022x |
|
CyberArk Software Ltd
NASDAQ:CYBR
|
0.055x |
|
King Slide Works Co Ltd
TW:2059
|
0.095x |
Annual Cash Flow Conversion Efficiency for Quest Diagnostics Incorporated (1996–2025)
The table below shows the annual cash flow conversion efficiency of Quest Diagnostics Incorporated from 1996 to 2025. For the full company profile with market capitalisation and key ratios, see Quest Diagnostics Incorporated (DGX) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $7.29 Billion | $1.89 Billion | 0.259x | +33.81% |
| 2024-12-31 | $6.90 Billion | $1.33 Billion | 0.193x | -2.40% |
| 2023-12-31 | $6.42 Billion | $1.27 Billion | 0.198x | -30.70% |
| 2022-12-31 | $6.01 Billion | $1.72 Billion | 0.286x | -15.95% |
| 2021-12-31 | $6.56 Billion | $2.23 Billion | 0.340x | +16.96% |
| 2020-12-31 | $6.89 Billion | $2.00 Billion | 0.291x | +34.90% |
| 2019-12-31 | $5.76 Billion | $1.24 Billion | 0.216x | -3.95% |
| 2018-12-31 | $5.34 Billion | $1.20 Billion | 0.225x | -3.78% |
| 2017-12-31 | $5.04 Billion | $1.18 Billion | 0.233x | +3.41% |
| 2016-12-31 | $4.74 Billion | $1.07 Billion | 0.226x | +33.26% |
| 2015-12-31 | $4.78 Billion | $810.00 Million | 0.169x | -21.82% |
| 2014-12-31 | $4.33 Billion | $938.00 Million | 0.217x | +32.00% |
| 2013-12-31 | $3.97 Billion | $652.00 Million | 0.164x | -42.13% |
| 2012-12-31 | $4.19 Billion | $1.19 Billion | 0.284x | +17.65% |
| 2011-12-31 | $3.71 Billion | $895.50 Million | 0.241x | -12.59% |
| 2010-12-31 | $4.05 Billion | $1.12 Billion | 0.276x | +10.91% |
| 2009-12-31 | $4.01 Billion | $997.40 Million | 0.249x | -15.69% |
| 2008-12-31 | $3.60 Billion | $1.06 Billion | 0.295x | +5.76% |
| 2007-12-31 | $3.32 Billion | $926.92 Million | 0.279x | -11.56% |
| 2006-12-31 | $3.02 Billion | $951.90 Million | 0.315x | +2.29% |
| 2005-12-31 | $2.76 Billion | $851.58 Million | 0.308x | -11.69% |
| 2004-12-31 | $2.29 Billion | $798.78 Million | 0.349x | +26.10% |
| 2003-12-31 | $2.39 Billion | $662.80 Million | 0.277x | -17.91% |
| 2002-12-31 | $1.77 Billion | $596.37 Million | 0.337x | -3.30% |
| 2001-12-31 | $1.34 Billion | $465.80 Million | 0.349x | -2.63% |
| 2000-12-31 | $1.03 Billion | $369.45 Million | 0.358x | +23.87% |
| 1999-12-31 | $863.10 Million | $249.50 Million | 0.289x | +16.10% |
| 1998-12-31 | $567.90 Million | $141.40 Million | 0.249x | -23.50% |
| 1997-12-31 | $541.70 Million | $176.30 Million | 0.325x | +298.14% |
| 1996-12-31 | $538.72 Million | $-88.49 Million | -0.164x | -- |
About Quest Diagnostics Incorporated
Quest Diagnostics Incorporated provides diagnostic testing and services in the United States. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It also provides services under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagn… Read more